Brand name – Iclusig
Generic name – Ponatinib
Salt composition – Ponatinib
Manufacturer – ARIAD
Dosage form – Oral (tablet)
Packaging – Bottle
Indication – Blood cancer
Storage – Stored at room temperature.
Strength – 15 mg, 45 mg
Gender – Unisex
Prescription required – Yes
Description
Iclusig (Ponatinib 45mg) tablet is used in the treatment of adults with leukaemia (cancer of the white blood cells). It is used to treat the different stages of chronic myeloid leukemia (CML), namely chronic, accelerated, and blast phases. It is also used in the treatment of acute lymphoblastic leukemia (ALL) in certain patients who are ‘Philadelphia-chromosome positive’, which means those patients whose genes have rearranged themselves to form another special type of a chromosome called ‘Philadelphia-chromosome’. This chromosome leads to the development of Leukaemia.
Pharmacodynamics
Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is active and works to promote the progression of CML.
This protein arises from the fused Bcr and Abl gene which is commonly known as the Philadelphia chromosome. Ponatinib is especially useful in the treatment of resistant
CML because it works to inhibit the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation highly confers resistance in cells. It prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Some other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors, and SRC families of kinases, and KIT, RET, TIE2, and FLT3.
Contraindications
This medicine is not indicated to patients who have a known allergy to any of the ingredients of this medicine.


